Michael Schlander
Overview
Explore the profile of Michael Schlander including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
67
Citations
630
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Doege D, Frick J, Eckford R, Koch-Gallenkamp L, Schlander M, Arndt V
Int J Cancer
. 2024 Oct;
156(4):711-722.
PMID: 39361297
Treatment modifications and contact restrictions were common during the COVID-19 pandemic and can be stressors for mental health. There is a lack of studies assessing pandemic-related risk factors for anxiety...
2.
Ubels J, Hernandez-Villafuerte K, Niebauer E, Schlander M
Health Care Anal
. 2024 Aug;
PMID: 39158650
Developing an instrument with the capability approach can be challenging, since the capability concept of Sen is ambiguous concerning the burdens that people experience whilst achieving their capabilities. A solution...
3.
Zaika V, Prakash M, Cheng C, Schlander M, Lang B, Beerenwinkel N, et al.
PLoS One
. 2024 May;
19(5):e0304374.
PMID: 38787836
Colonoscopy-based screening provides protection against colorectal cancer (CRC), but the optimal starting age and time intervals of screening colonoscopies are unknown. We aimed to determine an optimal screening schedule for...
4.
Muchadeyi M, Hernandez-Villafuerte K, Di Tanna G, Eckford R, Feng Y, Meregaglia M, et al.
Pharmacoeconomics
. 2024 Mar;
42(7):767-782.
PMID: 38551803
Background: The increasing number of studies that generate health state utility values (HSUVs) and the impact of HSUVs on cost-utility analyses make a robust tailored quality appraisal (QA) tool for...
5.
Schlander M, van Harten W, Retel V, Pham P, Vancoppenolle J, Ubels J, et al.
Lancet Oncol
. 2024 Mar;
25(4):e152-e163.
PMID: 38547899
Loss of income and out-of-pocket expenditures are important causes of financial hardship in many patients with cancer, even in high-income countries. The far-reaching consequences extend beyond the patients themselves to...
6.
Lwin M, Cheng C, Calderazzo S, Schramm C, Schlander M
Front Public Health
. 2024 Mar;
12:1307427.
PMID: 38454984
Background: Colorectal cancer (CRC) screening has been shown to be effective and cost-saving. However, the trend of rising incidence of early-onset CRC challenges the current national screening program solely for...
7.
Ubels J, Schlander M
Health Qual Life Outcomes
. 2023 Nov;
21(1):121.
PMID: 37950250
Background: Self-report instruments are used to evaluate the effect of interventions. However, individuals adapt to adversity. This could result in individuals reporting higher levels of well-being than one would expect....
8.
Pham P, Schlander M, Eckford R, Hernandez-Villafuerte K, Ubels J
Patient
. 2023 Jun;
16(5):515-536.
PMID: 37368196
Background: Multiple studies have indicated a socioeconomic impact of cancer and cancer care on patients and their families. Existing instruments designed to measure this impact lack consensus in their conceptualization...
9.
Hernandez D, Cheng C, Hernandez-Villafuerte K, Schlander M
Oncol Res
. 2023 Jun;
30(4):173-185.
PMID: 37304413
Lung cancer is the most common cancer type worldwide and has the highest and second highest mortality rate for men and women respectively in Germany. Yet, the role of comorbid...
10.
Schaefer R, Hernandez D, Barnighausen T, Kolominsky-Rabas P, Schlander M
Value Health
. 2023 Mar;
26(7):1032-1044.
PMID: 36921901
Objectives: This study aimed to test (official) evaluation criteria including the potential role of budget impact (BI) on health technology assessment (HTA) outcomes published by the Federal Joint Committee (Gemeinsamer...